JPWO2021093839A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021093839A5 JPWO2021093839A5 JP2022528124A JP2022528124A JPWO2021093839A5 JP WO2021093839 A5 JPWO2021093839 A5 JP WO2021093839A5 JP 2022528124 A JP2022528124 A JP 2022528124A JP 2022528124 A JP2022528124 A JP 2022528124A JP WO2021093839 A5 JPWO2021093839 A5 JP WO2021093839A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- -1 phenoxy, 2-fluorophenoxy Chemical group 0.000 claims 2
- 239000003909 protein kinase inhibitor Substances 0.000 claims 2
- 125000005554 pyridyloxy group Chemical group 0.000 claims 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000233805 Phoenix Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911109773.2 | 2019-11-13 | ||
| CN201911109773 | 2019-11-13 | ||
| CN201911288492.8 | 2019-12-13 | ||
| CN201911288492 | 2019-12-13 | ||
| CN202010096582 | 2020-02-17 | ||
| CN202010096582.3 | 2020-02-17 | ||
| CN202010711270 | 2020-07-22 | ||
| CN202010711270.9 | 2020-07-22 | ||
| PCT/CN2020/128597 WO2021093839A1 (fr) | 2019-11-13 | 2020-11-13 | Composé pyrrolopyrimidine utilisé comme inhibiteur de btk et son utilisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506691A JP2023506691A (ja) | 2023-02-20 |
| JPWO2021093839A5 true JPWO2021093839A5 (fr) | 2023-02-28 |
| JP7473642B2 JP7473642B2 (ja) | 2024-04-23 |
Family
ID=75912541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528124A Active JP7473642B2 (ja) | 2019-11-13 | 2020-11-13 | Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230357248A1 (fr) |
| EP (1) | EP4059935A4 (fr) |
| JP (1) | JP7473642B2 (fr) |
| KR (1) | KR20220097455A (fr) |
| CN (2) | CN117551103A (fr) |
| WO (1) | WO2021093839A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761410B (zh) * | 2021-04-06 | 2023-08-25 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| WO2022213932A1 (fr) * | 2021-04-06 | 2022-10-13 | 广州必贝特医药股份有限公司 | Composé de pyrrolopyrimidinone et son utilisation |
| CN117794934A (zh) * | 2021-05-12 | 2024-03-29 | 浙江龙传生物医药科技有限公司 | 吡咯并嘧啶类化合物的晶型及其制备方法 |
| WO2023110970A1 (fr) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Inhibiteurs macrocycliques de btk |
| CN115894500B (zh) * | 2022-11-02 | 2024-05-28 | 中国药科大学 | 一种作为btk激酶抑制剂的化合物及其制备方法与用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3235B1 (ar) * | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| RU2018104702A (ru) * | 2012-08-06 | 2019-02-22 | Ацея Байосайенсиз Инк. | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ |
| EP3042903B1 (fr) * | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Composés hétéro-bicycliques substitués, compositions et leurs applications médicales |
| CN113307811B (zh) | 2015-12-23 | 2023-11-14 | 艾科尔公司 | 四氢吡喃基氨基-吡咯并嘧啶酮及其使用方法 |
| US11020398B2 (en) * | 2016-08-24 | 2021-06-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
-
2020
- 2020-11-13 CN CN202311079865.7A patent/CN117551103A/zh active Pending
- 2020-11-13 EP EP20887944.5A patent/EP4059935A4/fr active Pending
- 2020-11-13 WO PCT/CN2020/128597 patent/WO2021093839A1/fr unknown
- 2020-11-13 CN CN202080078768.4A patent/CN114728974B/zh active Active
- 2020-11-13 KR KR1020227018702A patent/KR20220097455A/ko active Search and Examination
- 2020-11-13 US US17/776,873 patent/US20230357248A1/en active Pending
- 2020-11-13 JP JP2022528124A patent/JP7473642B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| JP5005532B2 (ja) | １０−プロパルギル−１０−デアザアミノプテリンを用いるｔ細胞リンパ腫の治療 | |
| EP3672591B1 (fr) | Effet antitumoral synergique d'un inhibiteur de bcl-2 combiné avec du rituximab et/ou de la bendamustine ou d'un inhibiteur de bcl-2 combiné à chop | |
| KR20010101896A (ko) | 백혈구 수를 증대시키는 방법 및 조성물 | |
| JP2017537126A5 (fr) | ||
| RU2624446C2 (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| SK10602003A3 (en) | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin | |
| AU2020259565A1 (en) | Quinoline compound or pharmaceutically acceptable salt thereof for treating Ewing's sarcoma | |
| KR101401220B1 (ko) | 방사선 치료 증강제 | |
| EP2717884A1 (fr) | Utilisation de composés métallocènes pour le traitement du cancer | |
| JP2005532397A5 (fr) | ||
| US20100087458A1 (en) | Method of treating melanoma | |
| JP2016512818A (ja) | テトランドリンファミリーの医薬製剤及び方法 | |
| JPH05163148A (ja) | 抗腫瘍剤 | |
| CN113811302B (zh) | 激酶抑制剂的用途 | |
| JPWO2021093839A5 (fr) | ||
| EP2902028A1 (fr) | Composition médicamenteuse pour le traitement de tumeurs et application de celle-ci | |
| KR20220124739A (ko) | 암의 치료를 위한 병용 요법 | |
| JPH025735B2 (fr) | ||
| US20100087398A1 (en) | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions | |
| RU2646475C2 (ru) | Лечение диабета I и II типа | |
| EP0623346A1 (fr) | Inhibiteur de la metastase d'une tumeur maligne | |
| EP4349341A1 (fr) | Préparation pharmaceutique pour la prévention ou le traitement de la fibrose pulmonaire | |
| JPS6058726B2 (ja) | プリン誘導体を有効成分として含有する抗アレルギ−，鎮痛，鎮静剤 | |
| US4845284A (en) | Substituted 3-nitrobenzenesulfonamides useful as adjuncts in radiation therapy |